- Investing.com
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
CRO Sector Dynamics | Explore Fortrea's position in the competitive Contract Research Organization landscape, facing challenges from larger operators and industry uncertainties |
Financial Resilience | Delve into Fortrea's mixed financial performance, featuring revenue declines but promising margin improvements and upward earnings estimate revisions |
Strategic Crossroads | Uncover the impact of Fortrea's CEO departure on its strategic direction, amidst ongoing efficiency programs and market positioning efforts |
Future Outlook | Analyst price targets range from $5 to $25, reflecting varied perspectives on Fortrea's potential amid industry headwinds and operational improvements |
Metrics to compare | FTRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFTREPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −1.1x | −0.5x | |
PEG Ratio | 0.00 | 0.06 | 0.00 | |
Price/Book | 0.5x | 1.6x | 2.6x | |
Price / LTM Sales | 0.2x | 1.8x | 3.0x | |
Upside (Analyst Target) | 18.1% | 58.7% | 52.6% | |
Fair Value Upside | Unlock | 16.7% | 8.7% | Unlock |